Back to News
Market Impact: 0.1
Trevi Therapeutics Announces Upcoming Presentations at the European Respiratory Society (ERS) Congress 2026
Source: globenewswire.com
Healthcare & BiotechCompany Fundamentals
A presentation is scheduled by Professor Marlies Wijsenbeek on quality-of-life outcomes from the LCQ assessed in the Phase 2b CORAL trial of nalbuphine ER for IPF-related chronic cough. No results, effect sizes, or timelines were provided in the article text.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.00
More News
- Nvidia GPUs are everywhere. Here are the ways companies are accessing them
- Bank of America is bullish on these top stocks ahead of earnings
- As companies pour billions into Earth-based AI infrastructure, Google is taking the data center race off-planet
- How U.S. know-how is fracking Australia into a gas boom, from Texas oilmen to Trump’s energy secretary
- The world needs Ukraine’s grain. Its farmers are running out of reasons to plant
- Big Tech is betting $700 billion on AI. Healthcare will decide whether the bet pays off